Pediatrics. 1996 Jan;97(1):137-40.
The purpose of this statement is to inform practitioners about new information concerning lack of demonstrated clinical effectiveness of ribavirin in the treatment of infants with respiratory syncytial virus (RSV) disease. The intent of the new recommendation is to allow practitioners to decide whether ribavirin therapy is appropriate or not by taking into account the particular clinical situation and their own preferences. More definitive answers to the questions of ribavirin efficacy and effectiveness will require multi-institutional, prospective, randomized clinical trials. Recommendations may be modified as new information becomes available.
本声明的目的是向从业者通报有关利巴韦林治疗呼吸道合胞病毒（RSV）疾病婴儿缺乏已证实的临床疗效的新信息。新建议的意图是让从业者通过考虑具体临床情况和自身偏好来决定利巴韦林治疗是否合适。关于利巴韦林疗效和有效性问题的更确切答案将需要多机构、前瞻性、随机临床试验。随着新信息的出现，建议可能会有所修改。
